Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
33 hedge funds and large institutions have $9M invested in Viracta Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 4 closing their positions.
955% more call options, than puts
Call options by funds: $327K | Put options by funds: $31K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
44% more capital invested
Capital invested by funds: $6.25M → $9M (+$2.75M)
18% more funds holding
Funds holding: 28 → 33 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$520K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$298K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$87.8K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$47.6K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$31.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$865K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$752K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$25.7K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$13.7K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$151 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
26
Seaview Investment Managers
Miami,
Florida
| $2K | +$5 | +1 | +0.3% |
|
|
NCM
27
Nantahala Capital Management
New Canaan,
Connecticut
| – | -$865K | -197,615 | Closed |
|
28
Millennium Management
New York
| – | -$26 | -5,931 | Closed |
|
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$151 | -29 | -39% |
|
|
VFA
30
Valeo Financial Advisors
Carmel,
Indiana
| – | +$21 | +4 | New |
|
|
AA
31
Addison Advisors
Middlebury,
Vermont
| – | +$26 | +5 | New |
|
|
SPIA
32
Steward Partners Investment Advisory
New York
| – | +$94 | +18 | New |
|
VIRX Hedge Fund Activity: Q4 2020 in Review
33 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2020, worth a combined $9M — up 44% from $6.25M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VIRX positions and 4 closed out — a net gain of 5 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $520K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $865K sold.
- 33 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2020, up from 28 in Q3 2020.
- Funds reported $9M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2020, up 44% quarter-over-quarter.
- 9 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2020 and 4 closed out, a net change of +5 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2020 was Monashee Investment Management, an estimated $520K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2020 was Nantahala Capital Management, an estimated $865K sold.
Based on aggregated 13F filings for Q4 2020.